Urinary System Adenocarcinoma — Trials

Urinary System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 378
Recruiting: 195
Ph III recruiting: 14
Growth YoY: +1.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (279)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07084909	Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER)	withdrawn	Phase 2 / Phase 3	0	Lantheus Medical ImagingINDUSTRY	1	Dec 10, 2025	clinicaltrials
NCT03693573	A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma	withdrawn	Phase 3	0	Hoffmann-La RocheINDUSTRY	0	Nov 15, 2018